2924-09-6

Basic information

• Product Name: 5-BROMO-2-FLUOROANILINE
• Synonyms: 5-BROMO-2-FLUOROANILINE;2-Fluoro-5-Bromoaniline;5-Bromo-2-fluoro Aniline 2924-9-6;5-Bromo-2-fluoroaniline ,98%;5-BROMO-2-FLUOROANIL;1-Amino-5-bromo-2-fluorobenzene;Benzenamine, 5-bromo-2-fluoro-;5-Bromo-2-fuoroaniline
• CAS NO: 2924-09-6
• Molecular Formula: C₆H₅BrFN
• Molecular Weight: 190.01
• Product Categories: Anilines, Aromatic Amines and Nitro Compounds;Phenol&Thiophenol&Mercaptan;Benzenes;Aniline series
• Mol File: 2924-09-6.mol

Chemical Properties

• Melting Point: 27℃
• Boiling Point: 105 °C / 12mmHg
• Flash Point: 27 °C
• Appearance: /Solid
• Density: 1.694 g/cm³
• Vapor Pressure: 0.0843mmHg at 25°C
• Refractive Index: 1.596
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 2.13±0.10(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 5-BROMO-2-FLUOROANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-FLUOROANILINE(2924-09-6)
• EPA Substance Registry System: 5-BROMO-2-FLUOROANILINE(2924-09-6)

Safety Data

• Hazard Codes: T,Xi,Xn
• Statements: 22-36-52-36/37/38-20/21/22
• Safety Statements: 26-60-36/37-9
• RIDADR: 2811
• HazardClass: IRRITANT, TOXIC
• Hazardous Substances Data: 2924-09-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-BROMO-2-FLUOROANILINE is used as a pharmaceutical intermediate for the synthesis of various drugs. Its chemical properties make it a valuable component in the development of new medications, contributing to the advancement of pharmaceutical research and drug discovery.
As a chemical intermediate, 5-BROMO-2-FLUOROANILINE plays a significant role in the production of different pharmaceutical compounds, which can be used for various medical applications, such as treating diseases, managing symptoms, or enhancing the effectiveness of existing treatments.

InChI:InChI=1/C6H5BrFN/c7-4-1-2-5(8)6(9)3-4/h1-3H,9H2

Upstream product

• 364-73-8 4-Bromo-1-fluoro-2-nitrobenzene 
• 63213-03-6 1,2-bis(3-bromophenyl)diazene 
• 1493-27-2 ortho-nitrofluorobenzene 
• 364-76-1 4-Fluoro-3-nitroaniline 

Downstream Products

• 214915-64-7 4-[(5-bromo-2-fluoro-phenyl)-hydrazono]-butan-1-ol 
• 2369-25-7 4-amino-3-fluorobenzenesulfonic acid 
• 121-57-3 4-aminobenzene sulfonic acid 
• 627871-08-3 (5-bromo-2-fluorophenyl)hydrazine 
• 474710-06-0 benzhydrylidene-(5-bromo-2-fluorophenyl)-amine 
• 116272-41-4 4-bromo-1-fluoro-2-iodobenzene 
• 71216-20-1 5-bromo-1,3-benzothiazole-2-thiol 
• 1453206-22-8 C₅₂H₃₀F₆N₂ 
• 1453206-25-1 C₅₂H₃₀F₆N₂ 
• 1374298-69-7 5-cyclopropyl-2-fluoroaniline 
• 1231892-80-0 2-fluoro-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)phenylamine 
• 348-54-9 2-Fluoroaniline 
• 873566-75-7 (3-amino-4-fluoro-phenyl)boronic acid 

Relevant articles and documents

1,3-dibromo-4-fluorobenzene preparation method

The invention discloses an industrial preparation method of 1,3-dibromo-4-fluorobenzene. The industrial preparation method of 1,3-dibromo-4-fluorobenzene comprises the steps that o-fluoronitrobenzeneserves as an initial raw material, and 1,3-dibromo-4-fluorobenzene is synthesized through bromine applying, reduction and diazotization-Sandmeyer three step reactions. The obtained 1,3-dibromo-4-fluorobenzene is yellow oily liquid, the purity is 97.5%, the raw material conversion rates of all steps each reach 100%, and the total recovery of the whole process reaches 52.7%.

Anion ligand promoted selective C-F bond reductive elimination enables C(sp2)-H fluorination

A detailed mechanism study on the anion ligand promoted selective C-H bond fluorination is reported. The role of the anion ligand has been clarified by experimental evidence and DFT calculations. Moreover, the nitrate promoted C-F bond reductive elimination enabled a selective C-H bond fluorination of various symmetric and asymmetric azobenzenes to access diverse o-fluoroanilines.

A 3-amino-4-fluorophenylboronic acid synthesis method

The invention discloses a synthetic method for 3-amino-4-fluorophenylboronic acid. The method includes the steps of conducting bromination on o-fluoronitrobenzene, conducting reduction to generate 5-bromo-2-fluoroanil, making 5-bromo-2-fluoroanil and tetrahydroxydiboron react in a coupled mode to generate the product, namely, 3-amino-4-fluorophenylboronic acid. According to the method, raw materials can be easily obtained, and operation is easy and convenient. The method is an appropriate route for preparing 3-amino-4-fluorophenylboronic acid.

Discovery of selective N-[3-(1-methyl-piperidine-4-carbonyl)-phenyl]-benzamide-based 5-HT1F receptor agonists: Evolution from bicyclic to monocyclic cores

Preclinical experiments and clinical observations suggest the potential effectiveness of selective 5-HT1F receptor agonists in migraine. Identifying compounds with enhanced selectivity is crucial to assess its therapeutic value. Replacement of the indole nucleus in 2 (LY334370) with a monocyclic phenyl ketone moiety generated potent and more selective 5-HT1F receptor agonists. Focused SAR studies around this central phenyl ring demonstrated that the electrostatic and steric interactions of the substituent with both the amide CONH group and the ketone C=O group play pivotal roles in affecting the adopted conformation and thus the 5-HT1F receptor selectivity. Computational studies confirmed the observed results and provide a useful tool in the understanding of the conformational requirements for 5-HT1F receptor agonist activity and selectivity. Through this effort, the 2-F-phenyl and N-2-pyridyl series were also identified as potent and selective 5-HT1F receptor agonists.

CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS

Provided are cyclopropanecarboxamido-substituted aromatic compounds that inhibit protein kinases and their use in anti-tumor area. In particular, tyrosine-kinase inhibitors and Raf-kinase inhibitors as anti-tumor agents, their preparation, pharmaceutical composition, and their use in the treatment of cancer are also provided.

CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS

Provided are cyclopropanecarboxamido-substituted aromatic compounds that inhibit protein kinases and their use in anti-tumor area. In particular, tyrosine-kinase inhibitors and Raf-kinase inhibitors as anti-tumor agents, their preparation, pharmaceutical composition, and their use in the treatment of cancer are also provided.

Selective reduction of halogenated nitroarenes with hydrazine hydrate in the presence of Pd/C

A large variety of halogenated nitroarenes have been selectively reduced with hydrazine hydrate in the presence of Pd/C to give the corresponding (halogenated) anilines in good yield.

2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors

The present invention provides 2-pyrimidinyl pyrazolopyridine compounds, compositions containing the same, as well as processes for the preparation and their use as pharmaceutical agents.

2-Pyrimidinyl Pyrazolopyridine Erbb Kinase Inhibitors

The present invention provides 2-pyrimidinyl pyrazolopyridine compounds, compositions containing the same, as well as processes for the preparation and their use as pharmaceutical agents.

METHODS FOR PREPARING INDAZOLE COMPOUNDS

The invention relates to methods for preparing compounds of formula (I): or pharmaceutically acceptable salts or solvates thereof. Compounds of the formula (I) are useful as anti-angiogenesis agents and as agents for modulating and/or inhibiting the activity of protein kinases, thus providing treatments for cancer or other diseases associated with cellular proliferation mediated by protein kinases.